Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2013-06-21 Capital/Financing Update
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 21, 2013, by TG Therapeutics, Inc. The key content is the announcement of entering into an At-the-Market Issuance Sales Agreement with MLV & Co. LLC, allowing the company to issue and sell shares of common stock up to $50 million. This is a clear update on the company's capital raising activities and financing arrangements. There are no financial statements or detailed financial results presented, only the description of the financing agreement and related terms. The document length is 4251 characters, which is relatively short and focused on a specific financing event. Therefore, this filing fits best under the category of Capital/Financing Update (CAP).
2013-06-21 English
PROSPECTUS SUPPLEMENT - RULE 424(B)(5)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an at-the-market offering of common stock. It details the terms of the offering, use of proceeds, risk factors, and plan of distribution. It is a capital raising document describing a financing activity rather than a financial report or earnings release. The presence of terms like 'Prospectus Supplement', 'At-the-Market Issuance Sales Agreement', and details about share sales and underwriting commissions clearly indicate this is a Capital/Financing Update. The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice but a full prospectus supplement. Therefore, the correct classification is Capital/Financing Update (CAP).
2013-06-21 English
Regulatory Filings 2013
Regulatory Filings
2013-06-18 English
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a regulatory filing process, specifically about the timing of the effectiveness of a registration statement. The document does not contain financial data, audit information, or detailed report content. It is a formal regulatory communication rather than a report or announcement of financial results. Given the short length (1711 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2013-06-17 English
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It is a correspondence related to a securities registration filing, not a financial report or earnings release. The document is short (1713 characters) and serves as a regulatory communication rather than a report containing financial data or analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2013-06-15 English
Regulatory Filings 2013
Regulatory Filings
2013-06-12 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.